The outlook of companies tied to Viagra's legacy presents a intricate investment scenario . While the initial boom generated substantial returns , generic competition have significantly eroded revenue. Investing in related pharmaceutical businesses now requires a careful assessment of patent safeguards, evolving healthcare changes, and the potentia